Would Your Spravato® Documentation PAAS an Audit?
Spravato® is a Schedule III controlled substance intranasal spray used in conjunction with an oral antidepressant for treatment-resistant depression in adults. It is part of the Risk Evaluation and Mitigation Strategy (REMS) Program and can only be dispensed and administered to patients in a REMS certified healthcare setting due to the risks of sedation, misuse, and abuse. PAAS National® alerted members in a February 2021 Newsline article How to Avoid Spravato® Audit Recoupments that we have seen attempted audit recoupments for Spravato® due to the pharmacy being unable to provide record of shipment received and dispensing information (including patient name, dose, number of devices, and date dispensed) per REMS guidelines. PBMs currently auditing Spravato® prescriptions include Elixir, MedImpact, Humana and Pharmacy Data Management, Inc. (PDMI.)
PAAS Tips:
- Biosimilar Advancements: Understanding the Latest Updates on Humira® with Cyltezo® and Abrilada™ - October 30, 2023
- $32 Million Kickback Scheme Involving Medicare and TRICARE - October 16, 2023
- Breyna™ – The First FDA Approved Symbicort® Generic With a 0.1 Gram Problem - October 14, 2023